CTOs on the Move

CancerLinQ

www.cancerlinq.org

 
CancerLinQ, a subsidiary of ASCO, is a mission-driven, non-profit health technology company focused on improving quality of care, advancing biomedical research, and improving health outcomes for all patients with cancer. Backed by ASCO, CancerLinQ`s products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. We are bilingual by design: fluent in both the language of oncology and technology. As a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cancerlinq.org
  • 2318 Mill Road Suite 600
    Alexandria, VA USA 22314
  • Phone: 703.299.0158

Executives

Name Title Contact Details
Anil Nair
Chief Technology Officer Profile

Similar Companies

Brown Fertility

Founded by Dr. Samuel Brown, Brown Fertility is a fully comprehensive fertility clinic offering patients exceptional results through personalized care and affordable treatment plans. With over 15 years experience and the management of more than 5,000 IVF cycles, Dr. Samuel Brown consistently achieves success rates above the national average. From basic evaluation and testing to the most advanced procedures and treatments available, Brown Fertility is dedicated to Conceiving Miracles™.

Nexeon MedSystems

Nexeon MedSystems is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hanna Instruments

Hanna Instruments is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of primary care and speciality care medicines. We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. We invest in distinctive science in three main therapy areas where we believe we can make the most meaningful difference to patients: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity. Our science exploits our rare combination of capabilities in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare capabilities. We build on our own capabilities by collaborating with world-renowned scientists and academic institutions and partnering with like-minded science-led companies. Through leading in science, we are confident that we can transform the lives of people around the world and deliver value to our shareholders.

University HealthSystem Consortium

UHC, based in Oak Brook, Ill., and representing 0.7 of the academic medical centers in the United States, is an alliance of 84 academic medical centers and 80 associate members.